Trial · NCT03099304
Adverse events140
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 140
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Vehicle Twice Daily (BID) | 2 | 32 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Ruxolitinib Cream 0.15% Once Daily (QD) | 0 | 31 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Ruxolitinib Cream 0.5% QD | 1 | 45 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Ruxolitinib Cream 1.5% QD | 0 | 44 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Ruxolitinib Cream 1.5% BID | 2 | 130 | 2 |
| other | Acne | Skin and subcutaneous tissue disorders | Vehicle Twice Daily (BID) | 1 | 32 | 7 |
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib Cream 0.15% Once Daily (QD) | 4 | 31 | 4 |
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib Cream 0.5% QD | 5 | 45 | 12 |
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib Cream 1.5% QD | 4 | 44 | 5 |
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib Cream 1.5% BID | 12 | 130 | 14 |
| other | Application site erythema | General disorders | Vehicle Twice Daily (BID) | 1 | 32 | 1 |
| other | Application site erythema | General disorders | Ruxolitinib Cream 0.15% Once Daily (QD) | 2 | 31 | 2 |
| other | Application site erythema | General disorders | Ruxolitinib Cream 0.5% QD | 0 | 45 | 0 |
| other | Application site erythema | General disorders | Ruxolitinib Cream 1.5% QD | 3 | 44 | 3 |
| other | Application site erythema | General disorders | Ruxolitinib Cream 1.5% BID | 1 | 130 | 1 |
| other | Application site exfoliation | General disorders | Vehicle Twice Daily (BID) | 0 | 32 | 0 |
| other | Application site exfoliation | General disorders | Ruxolitinib Cream 0.15% Once Daily (QD) | 2 | 31 | 2 |
| other | Application site exfoliation | General disorders | Ruxolitinib Cream 0.5% QD | 0 | 45 | 0 |
| other | Application site exfoliation | General disorders | Ruxolitinib Cream 1.5% QD | 1 | 44 | 1 |
| other | Application site exfoliation | General disorders | Ruxolitinib Cream 1.5% BID | 2 | 130 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03099304/events